Skip to main content
Medical information Clinical review pending

Genetic Testing

SMARCB1 Gene Mental Retardation Autosomal Dominant Type 15 Genetic Test

This genetic test uses Next Generation Sequencing (NGS) to identify mutations in the SMARCB1 gene, which can be associated with certain types of mental retardation. It helps in diagnosing neurological disorders linked to this gene.

General information only: This page is not a diagnosis or personal medical advice. A qualified clinician should decide whether testing is appropriate and interpret results in context.

Review status: No completed medical review is recorded for this page.

Ask a question
Counselor guidance included Confidential handling Kenya-wide coordination

At a glance

Plan your test

Sample
Blood sample, Extracted DNA, or one drop of blood on an FTA card.
Results
Confirm with the laboratory before booking.
Preparation
Provide a detailed clinical history. Genetic counseling is recommended to establish a family pedigree chart.
Test priceKSh 40,000

Payment: M-Pesa and card options can be confirmed during booking.

Insurance & government schemes

Is this test covered for you?

We help you verify whether the SMARCB1 Gene Mental Retardation Autosomal Dominant Type 15 Genetic Test test can be claimed against your insurer, employer scheme or a Kenyan government health scheme — before you book. Coverage depends on your plan, clinical indication and your provider's rules; final approval always rests with them.

Talk to a claims advisor

Providers & schemes we can help you check

Government & public schemes

SHIF — Social Health Insurance Fund Linda Mama EduAfya NHIF (legacy cards)

Eligibility and benefits follow the current rules of the Social Health Authority (SHA) and applicable government programmes.

Private insurers & employer schemes

Jubilee Health AAR APA Britam CIC Madison Resolution Pioneer Minet Old Mutual GA Life Heritage + other licensed insurers

Names shown for identification only — listing does not imply partnership or guarantee of coverage.

Have these ready when we check

  • Insurer or scheme name & policy / member number
  • A clinician's request / prescription for the test
  • Pre-authorisation letter, if your plan requires one

Free coverage check

Ask us to verify your cover

Send your details and our claims team confirms what documents you need and whether pre-authorisation applies — usually the same working day.

+254

Used only to process your coverage check — see our Privacy Policy. Verification support is free and does not guarantee your provider will pay.

01

Start with fit

Is this the right test for you?

The best test starts with a clear clinical question. These are common reasons a clinician or family may consider this test.

  • ✓Individuals with symptoms suggestive of mental retardation.
  • ✓Family history of mental retardation or related neurological disorders.
  • ✓Developmental delays.
  • ✓To confirm a suspected diagnosis related to SMARCB1 gene mutations.
  • ✓Genetic counseling for families with a history of the condition.
02

In plain language

What this test helps you understand

This test helps identify mutations in the SMARCB1 gene associated with a specific form of autosomal dominant mental retardation, aiding in diagnosis and genetic counseling.
The SMARCB1 Gene Mental Retardation Autosomal Dominant Type 15 NGS Genetic DNA Test is a diagnostic tool that uses Next Generation Sequencing (NGS) technology. It looks for specific genetic changes (mutations) in the SMARCB1 gene. These changes can be linked to neurological conditions, including a specific type of mental retardation.

This test is important for individuals who may have symptoms related to the SMARCB1 gene or have a family history of similar conditions. Identifying these genetic factors can help healthcare providers understand the cause of the condition and guide management and treatment decisions.

This test specifically analyzes the SMARCB1 gene to detect mutations associated with autosomal dominant mental retardation. By identifying these mutations, healthcare providers can make more informed decisions about diagnosis and potential treatment pathways.

This test is recommended for individuals showing signs of mental retardation or those with a family history of neurological disorders potentially linked to the SMARCB1 gene. Factors suggesting consideration for this test include a family history of mental retardation, neurological symptoms in relatives, or developmental delays.

Taking this test can provide several benefits, such as confirming a genetic diagnosis, aiding in treatment decisions, understanding family health risks, and informing genetic counseling and family planning discussions.

After the test, results will be shared with your healthcare provider for interpretation. This will involve determining if a mutation is present and discussing its implications for health, treatment, and potential risks for family members. A follow-up discussion with a healthcare professional is essential for a complete understanding of the results.
03

Medical review status

Clinical review pending

A completed medical review is not recorded for this page. No clinician has endorsed the information shown here. Please discuss testing decisions with a qualified healthcare professional.

Meet the DNA Labs Kenya medical team →
04

A simple process

What happens next?

You do not have to navigate the test alone. We help you move from question to next step.

1

Speak with us

We check the test and answer your questions before collection.

2

Give your sample

Choose home collection or a coordinated hub visit in Kenya. We explain whether this test uses a cheek swab or blood draw.

3

Understand your report

A counselor helps you understand the result and the next steps.

05

Choose your collection

Home collection or a lab visit

We will explain the sample, preparation, and next steps before anything is collected.

Home collection

Choose a coordinated visit at home or another convenient location. Our team confirms the appointment and sample requirements in advance.

Lab or hub visit

Prefer to visit a coordinated location? We can guide you to the right hub and explain what to expect when you arrive.

Ask about locations →
PreparationProvide a detailed clinical history. Genetic counseling is recommended to establish a family pedigree chart.
SampleBlood sample, Extracted DNA, or one drop of blood on an FTA card.
MethodologyNext Generation Sequencing (NGS).
PrivacyYour sample and report are handled confidentially. Ask the team how your information is stored and shared.
This test specifically targets the SMARCB1 gene. It may not detect mutations in other genes that could cause similar symptoms. Confirm with the laboratory before booking.
06

Read your report

What common result terms mean

PositiveA finding was identified. Your clinician or counselor will explain what it means for your care.
NegativeThe specific finding tested for was not identified. It does not rule out every possible cause.
VUSA variant was found, but current evidence is not enough to classify it. Your counselor can explain follow-up.
07

Questions people ask

Frequently asked questions

The SMARCB1 gene provides instructions for making a protein important for normal development and cell function. Mutations in this gene can lead to certain health problems.
Individuals with symptoms of mental retardation or a family history of neurological disorders linked to the SMARCB1 gene should discuss this test with their doctor.
The test is performed using a sample of blood or DNA. Next Generation Sequencing (NGS) technology is used to analyze the SMARCB1 gene.
Results will indicate whether specific mutations in the SMARCB1 gene were found. Your doctor will interpret the results and discuss their meaning with you.
Yes, genetic counseling is recommended before and after testing to help understand the implications of the test and its results for you and your family.
We have branches in major cities like Nairobi, Mombasa, and Kisumu, and offer home sample collection services. Contact us for details.
08

Collaboration

Open for partnership with hospitals, clinics, doctors & researchers

Whether you are referring patients, building a research programme or supporting students, we work as an extension of your team — with responsive communication and clear scientific standards.

Hospitals & clinics

Referral pathways, coordinated sample logistics and shared reporting that fits your clinical workflow.

Doctors & specialists

LOINC-coded reports, ACMG-based variant classification and a direct scientific line for complex cases.

Research institutions

Sanger sequencing, NGS panels and custom assays — with project design support, batch pricing and agreed turnaround commitments.

Students & academic projects

Discounted laboratory services for college, master's and PhD research projects — including proposal guidance and cost-effective batch testing.

Explore partnerships
09

Trust & transparency

Sources, standards & how this page is maintained

Standards & references

  • ACMG/AMP technical standards for sequence variant interpretation
  • ClinGen curation and gene–disease validity frameworks where applicable
  • LOINC-coded reporting for interoperable results
  • ISO 9001:2015 quality management; ISO 15189 accreditation in progress

Page provenance

  • Last updated: September 27, 2026
  • Medical review: not yet completed
  • Written for patients & clinicians in Kenya; reviewed periodically against current guidance

Medical disclaimer: this page is general information, not a diagnosis or personal medical advice. Testing decisions and result interpretation should be made with a qualified healthcare professional.

Keep exploring

Related tests

View all tests →
Chat on WhatsApp